TNDM Stock Analysis: Tandem Diabetes Care | NASDAQ
Medical Devices | NASDAQ, USA | Market Cap: 1.213m USD | 12M Return: 31% | US8753722037 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 34.8M
Qual. Beats: 0
Rev. Trend: 79.8%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Tandem Diabetes Care, Inc. (NASDAQ: TNDM) is a U.S.-based medical device company that designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. Its flagship products are the t:slim X2 insulin delivery system and the Tandem Mobi automated insulin pump. The company also generates recurring revenue from single-use products such as insulin cartridges and infusion sets, and offers complementary software tools including the Tandem Device Updater, the Tandem Source data management platform, and the Sugarmate mobile app. Tandem maintains a research collaboration with the University of Virginia Center for Diabetes Technology focused on fully automated closed-loop insulin delivery. Originally incorporated in 2006 as Phluid Inc., the company adopted its current name in January 2008 and is headquartered in San Diego, California.
The company operates within the diabetes care device segment of the health care equipment industry, where it competes in a market that also includes established players such as Medtronic and Insulet. A typical business model in this sector pairs durable hardware (the pump) with high-margin, recurring consumable revenue from disposable cartridges and infusion sets, which is a key driver of long-term profitability for manufacturers in the space.
- Tandem Mobi shipments accelerate against Insulet Omnipod competition
- Gross margin expansion drives path to sustained profitability
- Type 2 diabetes label expansion unlocks new patient pool
| Net Income: -63.3m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.02 > 0.02 and ΔFCF/TA -1.42 > 1.0 |
| NWC/Revenue: 52.97% < 20% (prev 32.39%; Δ 20.58% < -1%) |
| CFO/TA -0.00 > 3% & CFO -5.52m > Net Income -63.3m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 3.18 > 1.5 & < 3 |
| Outstanding Shares: last quarter (68.4m) vs 12m ago 2.01% < -2% |
| Gross Margin: 56.01% > 18% (prev 46.95%; Δ 9.06% > 0.5%) |
| Asset Turnover: 102.6% > 50% (prev 128.0%; Δ -25.41% > 0%) |
| Interest Coverage Ratio: -6.42 > 6 (EBIT TTM -52.8m / Interest Expense TTM 8.22m) |
| A: 0.48 (Total Current Assets 804.6m - Total Current Liabilities 253.0m) / Total Assets 1.15b |
| B: -1.12 (Retained Earnings -1.29b / Total Assets 1.15b) |
| C: -0.05 (EBIT TTM -52.8m / Avg Total Assets 1.01b) |
| D: 0.13 (Book Value of Equity 130.4m / Total Liabilities 1.02b) |
| Altman-Z'' = -0.74 = B |
| DSRI: 1.36 (Receivables 162.1m/128.4m, Revenue 1.04b/1.12b) |
| GMI: 0.84 (GM 46.95% / 56.01%) |
| AQI: 1.47 (AQ_t 0.14 / AQ_t-1 0.10) |
| SGI: 0.93 (Revenue 1.04b / 1.12b) |
| TATA: -0.05 (NI -63.3m - CFO -5.52m) / TA 1.15b) |
| Beneish M = -2.65 (Cap -4..+1) = A |
As of October 31, 2026, the stock is trading at USD 19.11 with a total of 1,874,190 shares traded. Over the past week, the price has changed by +9.64%, over one month by +15.33%, over three months by +0.53% and over the past year by +30.98%.
Current recommended Stop Loss: 16.90 (which is 11.6% or 2.3 ATR below the current price).
Tandem Diabetes Care has received a consensus analysts rating of 3.96. Therefore, it is recommended to buy TNDM.
- StrongBuy: 11
- Buy: 2
- Hold: 12
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 27.8 | 45.3% |
P/E Forward = 1111.1111
P/S = 1.1645
P/B = 6.6463
Revenue TTM = 1.04b USD
EBIT TTM = -52.8m USD
EBITDA TTM = -34.8m USD
Long Term Debt = 602.6m USD (from longTermDebt, last quarter)
Short Term Debt = 20.3m USD (from shortTermDebt, last quarter)
Debt = 875.9m USD (from shortLongTermDebtTotal, last quarter) + Leases 136.7m
Net Debt = 419.9m USD (calculated: Debt 875.9m - CCE 456.0m)
Enterprise Value = 1.63b USD (1.21b + Debt 875.9m - CCE 456.0m)
Interest Coverage Ratio = -6.42 (Ebit TTM -52.8m / Interest Expense TTM 8.22m)
EV/FCF = -61.34x (Enterprise Value 1.63b / FCF TTM -26.6m)
FCF Yield = -1.63% (FCF TTM -26.6m / Enterprise Value 1.63b)
FCF Margin = -2.56% (FCF TTM -26.6m / Revenue TTM 1.04b)
Net Margin = -6.08% (Net Income TTM -63.3m / Revenue TTM 1.04b)
Gross Margin = 56.01% ((Revenue TTM 1.04b - Cost of Revenue TTM 458.1m) / Revenue TTM)
Gross Margin QoQ = 56.87% (prev 55.33%)
Tobins Q-Ratio = 1.41 (Enterprise Value 1.63b / Total Assets 1.15b)
Interest Expense / Debt = 0.94% (Interest Expense 8.22m / Debt 875.9m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -41.7m (EBIT -52.8m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 3.18 (Total Current Assets 804.6m / Total Current Liabilities 253.0m)
Debt / Equity = 6.72 (Debt 875.9m / totalStockholderEquity, last quarter 130.4m)
Debt / EBITDA = -12.06 (negative EBITDA) (Net Debt 419.9m / EBITDA -34.8m)
Debt / FCF = -15.78 (negative FCF - burning cash) (Net Debt 419.9m / FCF TTM -26.6m)
Total Stockholder Equity = 137.7m (last 4 quarters mean from totalStockholderEquity)
RoA = -6.24% (Net Income -63.3m / Total Assets 1.15b)
RoE = -45.97% (Net Income TTM -63.3m / Total Stockholder Equity 137.7m)
RoCE = -7.13% (EBIT -52.8m / Capital Employed (Equity 137.7m + L.T.Debt 602.6m))
RoIC = -4.80% (negative operating profit) (NOPAT -41.7m / Invested Capital 869.4m)
WACC = 5.39% (E(1.21b)/V(2.09b) * Re(8.75%) + D(875.9m)/V(2.09b) * Rd(0.94%) * (1-Tc(0.21)))
Discount Rate = 8.75% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 98.16 | Cagr: 2.06%
[DCF] Fair Price = unknown (Cash Flow -26.6m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.28 | # QB: 0
Revenue Correlation: 79.84 | Revenue CAGR: 14.58% | SUE: -0.01 | # QB: 0
EPS current Quarter (2026-09-30): EPS=-0.24 | Chg30d=+0.87% | Revisions=-50% | Analysts=20
EPS current Year (2026-12-31): EPS=-0.66 | Chg30d=+0.48% | Revisions=+0% | GrowthEPS=+74.3% | GrowthRev=+5.7%
EPS next Year (2027-12-31): EPS=0.16 | Chg30d=-6.85% | Revisions=+0% | GrowthEPS=+123.9% | GrowthRev=+12.3%
[Analyst] Revisions Ratio: -41% (up=5, down=14)